1
|
Vavers E, Zvejniece L, Maurice T, Dambrova M. Allosteric Modulators of Sigma-1 Receptor: A Review. Front Pharmacol 2019; 10:223. [PMID: 30941035 PMCID: PMC6433746 DOI: 10.3389/fphar.2019.00223] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2018] [Accepted: 02/22/2019] [Indexed: 11/13/2022] Open
Abstract
Allosteric modulators of sigma-1 receptor (Sig1R) are described as compounds that can increase the activity of some Sig1R ligands that compete with (+)-pentazocine, one of the classic prototypical ligands that binds to the orthosteric Sig1R binding site. Sig1R is an endoplasmic reticulum membrane protein that, in addition to its promiscuous high-affinity ligand binding, has been shown to have chaperone activity. Different experimental approaches have been used to describe and validate the activity of allosteric modulators of Sig1R. Sig1R-modulatory activity was first found for phenytoin, an anticonvulsant drug that primarily acts by blocking the voltage-gated sodium channels. Accumulating evidence suggests that allosteric Sig1R modulators affect processes involved in the pathophysiology of depression, memory and cognition disorders as well as convulsions. This review will focus on the description of selective and non-selective allosteric modulators of Sig1R, including molecular structure properties and pharmacological activity both in vitro and in vivo, with the aim of providing the latest overview from compound discovery approaches to eventual clinical applications. In this review, the possible mechanisms of action will be discussed, and future challenges in the development of novel compounds will be addressed.
Collapse
Affiliation(s)
- Edijs Vavers
- Laboratory of Pharmaceutical Pharmacology, Latvian Institute of Organic Synthesis, Riga, Latvia
| | - Liga Zvejniece
- Laboratory of Pharmaceutical Pharmacology, Latvian Institute of Organic Synthesis, Riga, Latvia
| | - Tangui Maurice
- MMDN, University of Montpellier, INSERM, EPHE, UMR-S1198, Montpellier, France
| | - Maija Dambrova
- Laboratory of Pharmaceutical Pharmacology, Latvian Institute of Organic Synthesis, Riga, Latvia
| |
Collapse
|
2
|
Baudry A, Alleaume-Butaux A, Dimitrova-Nakov S, Goldberg M, Schneider B, Launay JM, Kellermann O. Essential Roles of Dopamine and Serotonin in Tooth Repair: Functional Interplay Between Odontogenic Stem Cells and Platelets. Stem Cells 2015; 33:2586-95. [PMID: 25865138 DOI: 10.1002/stem.2037] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2014] [Revised: 03/06/2015] [Accepted: 03/28/2015] [Indexed: 12/11/2022]
Abstract
Characterizing stem cell intrinsic functions is an ongoing challenge for cell therapies. Here, we report that two independent A4 and H8 stem cell lines isolated from mouse molar pulp display the overall functions of bioaminergic cells. Both clones produce neurotrophins and synthesize, catabolize, store, and transport serotonin (5-hydroxytryptamine [5-HT]) and dopamine (DA). They express 5-HT1D,2B,7 and D1,3 autoreceptors, which render pulpal stem cells competent to respond to circulating 5-HT and DA. We show that injury-activated platelets are the source of systemic 5-HT and DA necessary for dental repair since natural dentin reparation is impaired in two rat models with monoamine storage-deficient blood platelets. Moreover, selective inhibition of either D1, D3, 5-HT2B, or 5-HT7 receptor within the pulp of wild-type rat molars after lesion alters the reparative process. Altogether our data argue that 5-HT and DA coreleased by pulp injury-activated platelets are critical for stem cell-mediated dental repair through 5-HT and DA receptor signalings.
Collapse
Affiliation(s)
- Anne Baudry
- INSERM UMR-S 1124, Cellules Souches, Signalisation et Prions, Paris, France.,Université Paris Descartes, Sorbonne Paris Cité, UMR-S 1124, Paris, France
| | - Aurélie Alleaume-Butaux
- INSERM UMR-S 1124, Cellules Souches, Signalisation et Prions, Paris, France.,Université Paris Descartes, Sorbonne Paris Cité, UMR-S 1124, Paris, France
| | - Sasha Dimitrova-Nakov
- INSERM UMR-S 1124, Cellules Souches, Signalisation et Prions, Paris, France.,Université Paris Descartes, Sorbonne Paris Cité, UMR-S 1124, Paris, France
| | - Michel Goldberg
- INSERM UMR-S 1124, Cellules Souches, Signalisation et Prions, Paris, France.,Université Paris Descartes, Sorbonne Paris Cité, UMR-S 1124, Paris, France
| | - Benoît Schneider
- INSERM UMR-S 1124, Cellules Souches, Signalisation et Prions, Paris, France.,Université Paris Descartes, Sorbonne Paris Cité, UMR-S 1124, Paris, France
| | - Jean-Marie Launay
- AP-HP, Service de Biochimie, Hôpital Lariboisière, Paris, France.,INSERM U942, Hôpital Lariboisière, Paris, France.,Pharma Research Department, F. Hoffmann-La-Roche, Ltd, Basel, Switzerland
| | - Odile Kellermann
- INSERM UMR-S 1124, Cellules Souches, Signalisation et Prions, Paris, France.,Université Paris Descartes, Sorbonne Paris Cité, UMR-S 1124, Paris, France
| |
Collapse
|
3
|
The Discovery of Novel Selective D1 Dopaminergic Agonists: A-68930, A-77636, A-86929, and ABT-413. INTERNATIONAL JOURNAL OF MEDICINAL CHEMISTRY 2011; 2011:424535. [PMID: 25954518 PMCID: PMC4412209 DOI: 10.1155/2011/424535] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/04/2010] [Accepted: 02/17/2011] [Indexed: 01/14/2023]
Abstract
The novel selective D1 dopaminergic full agonists A-68930, A-77636 were discovered by the synthesis of molecules to probe the bioactive conformation of the partial agonist SKF-38393, by the use of this information to add D1 affinity and selectivity to a screening hit, and by traditional medicinal chemistry exploration of structure-activity relationships. The subsequent design of A-86929 and ABT-413 capitalized on these results, recently disclosed agonists, and traditional medicinal chemistry.
Collapse
|
4
|
Wikström H. 5 Centrally Acting Dopamine D2 Receptor Ligands: Agonists. PROGRESS IN MEDICINAL CHEMISTRY 1992; 29:185-216. [PMID: 1362000 DOI: 10.1016/s0079-6468(08)70008-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/25/2023]
Abstract
The collected amount of research on D2 agonists is immense. The D2 research field has been, and still is, very dynamic. Despite this fact, only a few compounds have reached the clinic so far. At present there are clinical trials ongoing with partial D2 agonists possessing a range of intrinsic efficacies. Some of these agonists are tested for their potential effects in Parkinson's disease (high intrinsic efficacy), while others are tested for potential anti-psychotic effects (low intrinsic efficacy). An interesting possibility has arisen through the research on the synergism between D1 and D2 receptors. This could possibly be utilized in the alleviation of Parkinsonian symptomatology. The near future will show whether the compounds under evaluation hold promise for being new, valuable medicines for treating major diseases like Parkinson's disease and schizophrenia.
Collapse
Affiliation(s)
- H Wikström
- Department of Pharmacology, University of Göteborg, Sweden
| |
Collapse
|